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Abstract
Background: The Gag protein of Mason-Pfizer monkey virus, a betaretrovirus, contains a
phosphoprotein that is cleaved into the Np24 protein and the phosphoprotein pp16/18 during virus
maturation. Previous studies by Yasuda and Hunter (J. Virology. 1998. 72:4095–4103) have
demonstrated that pp16/18 contains a viral late domain required for budding and that the Np24
protein plays a role during the virus life cycle since deletion of this N-terminal domain blocked virus
replication. The function of the Np24 domain, however, is not known.
Results: Here we identify a region of basic residues (KKPKR) within the Np24 domain that is highly
conserved among the phosphoproteins of various betaretroviruses. We show that this KKPKR
motif is required for virus replication yet dispensable for procapsid assembly, membrane targeting,
budding and release, particle maturation, or viral glycoprotein packaging. Additional experiments
indicated that deletion of this motif reduced viral RNA packaging 6–8 fold and affected the transient
association of Gag with nuclear pores.
Conclusion: These results demonstrate that the Np24 domain plays an important role in RNA
packaging and is in agreement with evidence that suggests that correct intracellular targeting of Gag
to the nuclear compartment is an fundamental step in the retroviral life cycle.
Introduction
Viruses of the Betaretroviruses genus, formerly known as D-
and B-type retroviruses, assemble their capsids in the cyto-
plasm of infected cells instead of at the plasma membrane
like most retroviruses. The B-type viruses contain promi-
nent surface glycoproteins and spherical, eccentric capsids
and include mouse mammary tumor virus (MMTV) and
exogenous and endogenous MMTV-like retroviruses in
mice and humans [1-3]. D-type viruses have less dense
surface spikes and contain cylindrical capsids. Exogenous
and endogenous D-type viruses infect in a variety of mam-
malian hosts including Old World monkeys (Mason-
Pfizer monkey virus [M-PMV], simian retrovirus 1 [SRV-
1], [SRV-2] and simian endogenous retrovirus) [4-6], New
World monkeys (squirrel monkey retrovirus [SMRV]) [7],
sheep and goats (Jaagsiekte sheep retrovirus and enzootic
nasal tumor virus respectively) [8-10]. D-type virus
sequences have also been detected in humans, the Austral-
ian common brushtail possum and mice (Trichosurus vul-
pecula endogenous retrovirus D, rabbit endogenous virus
H, and MusD, respectively) [11-13].
M-PMV, the prototypical D-type virus, was first isolated
from a mammary adenocarcinoma of a female Rhesus
monkey [14]. Although M-PMV was originally suspected
to be an oncogenic virus, it was later found to induce a
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sever "wasting" and immunodeficiency syndrome distinct
from that caused by immunosuppressive lentiviruses [15].
SRV-1 and SRV-2 are related to, yet serotypically distinct
from, M-PMV and were isolated from primates suffering
diseases similar to that caused by M-PMV [16,17].
M-PMV, the most thoroughly understood of the D-type
betaretroviruses, contains four genes (5'-gag-pro-pol-env).
As with other retroviruses, its Gag protein, Pr78, serves
multiple functions during the viral life cycle, including
virus assembly, virion maturation and early post-entry
steps in virus replication [18]. Multiple studies have
shown that Pr78 has the innate ability to assemble into
immature capsids or procapsids in the cytoplasm, recog-
nize and package the viral RNAs and glycoproteins and
facilitate budding from the plasma membrane. During
viral budding or shortly thereafter, Pr78 is cleaved by the
viral protease to yield the mature virion associated pro-
teins: matrix MA (p10), the phosphoprotein pp24, p12,
capsid (CA or p27), nucleocapsid (NC or p14) and p4.
These mature Gag-cleavage products then play roles dur-
ing the early stages of the viral life cycle where they may
help facilitate uncoating, reverse transcription and nuclear
entry of the viral DNA. The regions and modifications of
Pr78 required for these events have been partially identi-
fied.
Upon translation, Pr78 is targeted to a pericentriolar
region of the cytoplasm in close proximity to the nuclear
membrane where it assembles into spherical, procapsids
[19]. The signal within Pr78 responsible for this pericen-
triolar targeting (the cytoplasmic targeting/retention sig-
nal or CTRS) is located within an 18 amino acid sequence
of the matrix domain (MA). This motif is dominant over
the bipartite myristylation and lysine/arginine-rich bipar-
tite membrane targeting signals that is also located within
the MA domain. Insertion of the CTRS into the analogous
region of the MLV Gag protein, which normally assembles
at the plasma membrane, results in intracytoplasmic
assembly of MLV Gag. Secondly, substitution of an
arginine within the CTRS of M-PMV Gag to a tryptophan
(R55W) destroys the dominant CTRS function resulting in
capsid assembly at the plasma membrane [20].
Other regions of Pr78 are also essential for procapsid
assembly. Residues within the MA, yet separate from the
CTRS, and the CA domains are required for assembly [20-
23]. Likewise, the p12 domain with in Pr78 provides an
internal scaffolding that together with the cononical I
domain, which is located near the CA-NC junction, func-
tion to promote Gag-Gag interactions during capsid
[24,25]. Assembly of the spherical capsid also requires
interactions between the viral RNAs (vRNA) and Gag pro-
teins [26,27]. Thus, the vRNA must also be present at the
assembly site to provide this additional nucleation or scaf-
folding function. Although Gag-vRNA interaction occurs
primarily though interaction in the NC domain, other
regions of Gag appear to be important by targeting Gag to
the site of vRNA packaging and by imparting correct struc-
tural information upon Gag [22,28-32].
Following assembly, the procapsids are transported to the
plasma membrane from which they bud. Both the myris-
tyic acid modification of Pr78 and specific amino acids
within the MA domain play critical roles in plasma mem-
brane targeting [20,21]. Moreover, Sfakianos and Hunter
have shown that the M-PMV Env glycoproteins and
Rab11-positive recycling endosomes play critical roles in
transporting the preassembled procapsids from the peri-
centriolar assembly site to the plasma membrane [33].
Upon arrival of the procapsids at the plasma membrane,
a proline-rich PPPYX4PSAP motif located near the car-
boxy-terminus of the Gag phosphoprotein, pp24, pro-
vides the late budding domain (L), which facilitates viral
budding [34,35].
Upon release, nascent immature particles undergo a mat-
uration process to acquire infectivity. During this process,
Pr78 is cleaved by the viral protease to yield the seven pro-
teins: MA, pp24, p12, CA, NC, and p4. The phosphopro-
tein conserved among M-PMV, SRV-1, SRV-2, SERV, and
MMTV yet its function is only partially known. During M-
PMV maturation, pp24 is further cleaved into two pro-
teins; the C-terminal pp16 protein and the N-terminal
Np24 protein. Both are required for virus replication. Yas-
uda and Hunter demonstrated that the pp16 domain con-
tains the late budding motif and deletion of the Np24
domain completely blocked virus replication [35]. How-
ever, the function of Np24 was not determined. In this
study, we examined the role of the Np24 domain during
virus replication. We have identified a lysine-arginine rich
motif within Np24 that is conserved among many betaret-
rovirus and is essential for infectivity. The results pre-
sented here show that the KKPKR motif in Np24 is not
required for procapsid assembly, intracellular transport,
budding or glycoprotein incorporation but plays a critical
role in vRNA packaging.
Results
Deletion of the KR box in Np24 blocks virus replication
While it was previously determined that the Np24
domain of Pr78Gag is required for replication [35], the role
of this protein plays during the virus life cycle is not
known. To gain further insight into which regions(s) of
Np24 might be important for replication, the Np24 pro-
tein sequence was aligned to the analogous phosphopro-
teins from different infectious betaretroviruses (Fig. 1A).
As expected because of the close similarity between the
simian betaretroviruses M-PMV and SRV-1 and the more
distantly related SRV-2 and SERV, their phosphoprotein
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sequences are 82%, 62%, and 61% (respectively) similar
to M-PMV Np24. The most notable similarities occur at
the amino- and carboxy-terminal ends of theses phospho-
proteins. While the amino-terminal sequences are not
conserved in the phosphoproteins of MMTV and MMTV
related betaretroviruses, the highly conserved cluster of
positively charged amino acids, KKPKR, (the KR box) near
the carboxy-terminal end is shared by these betaretrovi-
ruses. In M-PMV (and SRV-1), the KR box is located near
the carboxy-terminal end of Np24. In MMTV, it is located
in the same relative position of pp21. The conservation of
the KR box within the phosphoproteins of these divergent
viruses suggests that it may be essential to virus replica-
tion. To determine if this motif (KKPKR) in M-PMV serves
an important role during the virus life cycle, PCR muta-
genesis was used to delete the region encoding the KKPKR
motif from the infectious clone pSARM4. The mutant,
p∆KKPKR, and wild-type pSARM4 proviral DNAs were
transfected into COS-1 cells. At 48 h post transfections the
viruses produced from the transfected cells were harvested
and assayed for RT activity. Wild-type M-PMV and
∆KKPKR-transfected cells produced equivalent amounts
of virus particles (data not shown). Viral spread assays
were then carried out to examine if the deletion of the
KKPKR motif affected viral replication. For this, Hos cells
were infected with equivalent amounts of wild-type and
mutant virus particles, normalized by RT activities. The
amounts of virus particles present in the supernatants of
infected cells at 2, 4, 8, 10, and 12 days post-infection
were determined by RT assays. While wild-type virus rep-
licated in Hos cells, as indicated by the increasing
amounts of RT activity in the culture medium over time,
no detectable RT activity was observed in the supernatants
of uninfected or ∆KKPKR-infected COS-1 cells even at 14
days post-infection (Fig. 1B). These data demonstrates
that deletion of the KKPKR motif blocked virus replica-
tion.
Assembly and release of ∆KKPKR mutant particles
Because the different morphogenic steps (procapsid
assembly, cytoplasmic transport, membrane biding, and
budding) are temporally separate for M-PMV, this virus
provides an ideal opportunity to determine which if any
of the late assembly steps might be affected by the dele-
tion mutation. To determine if the replication-defective
∆KKPKR mutant could assemble intracellular procapsids,
transfected cells were lysed in a TX-100 lysis buffer that
does not disrupt assembled procapsids. The assembled
procapsids were separated from the soluble unassembled
Gag proteins in the cellular lysates by centrifugation
through a 20% sucrose cushion. The pelleted proteins
were solublized directly in protein loading buffer, sepa-
rated by SDS-PAGE, and immunoblotted using anti-Pr78
antibodies. As expected, wild-type Gag (Pr78WT) was
detected in both the soluble fraction (unassembled) and
pelleted fractions (assembled procapsids) of the cellular
lysates (Fig 2A. Lanes 1 and 2). The presence of the
∆KKPKR mutant Gag protein (Pr78∆KR) in the soluble and
pelletable fractions (Fig. 2A lanes 4 and 5) indicates that
the mutant Gag proteins assembled into procapsids.
The rate of assembly and release of capsids from Pr78WT
and Pr78∆KR expressing cells were analyzed by pulse-chase
analyses to determine if the deletion had caused defects in
virus assembly and release. Transfected COS-1 cells were
pulse labeled with [35S] methionine-cysteine for 30 min.
and chased for 1, 2, 4, and 8 hours in complete growth
medium. Cell associated and released-virus-associated
proteins at each time point were analyzed by immunopre-
cipitation using rabbit anti-Pr78 antiserum (Fig. 2)
Similar levels of Gag (Pr78), Gag-Pro (Pr95), and Gag-
Pro-Pol (Pr180) fusion proteins were synthesized during
the pulse labeling by cells expressing wild-type M-PMV
The highly conserved KR box within the Np24 protein of M-PMV is required for viral replicationFigure 1
The highly conserved KR box within the Np24 protein of M-
PMV is required for viral replication. (A) Amino acid align-
ment of phosphoproteins of betaretroviruses showing areas 
of sequence conservation in the N-terminus and C-terminus. 
All conserved residues are bolded and the highly conserved 
KR box is shadowed. Accession Numbers; M-PMV (P07567), 
SRV-1 (AAA47730), SRV-2 (P51516), MMTV (AAF3147) (B) 
Viral replication measured by virus spread assay. Culture 
media from COS-1 cells transfected with nothing (Black), 
wild-type M-PMV proviral DNA, pSARM4 (Red), or ∆KKPKR 
proviral DNA (Blue) were collected and assayed for RT 
activity. HOS cells were infected with equal amounts of virus 
(normalized by RT activity). Virus spread in HOS cells was 
measured by RT assays at 2, 4, 6, 8, 10, 12, and 14 days post 
infection.
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(Fig. 2B). The 68 kDa protein is a N-terminal truncated
Gag protein that is expressed by initiation of translation at
an internal methionine codon of gag at position 100 [24].
As expected, the intensities of these wild-type Gag pro-
teins in the cell lysates decreased during the chase with a
concomitant appearance of p27 (CA). During or shortly
after virus release, Pr78WT is processed by the virus-
encoded protease into p10 (MA), Np24, pp16/18, p12,
p27 (CA), p14 (NC), and p4. Thus the appearance of p27
in the culture medium indicates that virus particles were
released and that Pr78WT was being processed normally
(Fig. 2B, lane 4). The other Gag cleavage products were
not detected because they either do not contain
methionines, or contain only a single methionine and
thus were not detected.
In cells expressing the mutant virus, similar levels of cell-
associated Gag precursors were observed in the pulse. Yas-
uda and Hunter [35] previously reported that deletion of
the entire Np24 domain from Pr78 caused a rapid turn
(A) Western Blot analysis of intracellular procapsid assembly using Gag fractionation techniquesFigure 2
(A) Western Blot analysis of intracellular procapsid assembly using Gag fractionation techniques. 48 hrs post transfection, 
COS-1 cells were lysed with and fractionated over a 20% sucrose cushion to separate assembled procapsids from unassembled 
Gag proteins. Pr78 in the fractionated samples were detected by western blot using rabbit anti-Pr78 antibodies. Soluble wild-
type Pr78 (lane 1); pelletable wild-type Pr78 (lane 2); untransfected (lane 3); soluble ∆KKPKR Pr78 (lane 4); pelletable ∆KKPKR 
Pr78 (lane 5). (B) Virus release kinetics. Transfected COS-1 cells pulsed labeled with [35S] methionine-cysteine for 30 minutes 
and chased for 0, 1, 2, 4, and 8 hours. Untransfected (lane 1); pSARM-4 (lanes 2–6); ∆KKRKR (lanes 7–11). Medium was col-
lected and cells were lysed at the appropriate times with 1× Buffer A. Cellular lysates and medium were adjusted to 1× lysis 
buffer B. Viral proteins were immunoprecipitated from all samples using rabbit anti-Pr78 antibodies and separated by SDS-
PAGE (12% acrylamyde) and detected by phospor-imaging.
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over of Pr78 in cells and thus decreased the amount of
particles released from cells. It was, therefore suggested
that the Np24 domain is important for Pr78 stability.
However, deletion of just the KKPKR motif did not alter
the intracellular stability of Pr78∆KR. Instead, the intensity
of Pr78∆KR decreased in the cell lysates in a manner similar
to Pr78WT. This was accompanied by a slightly reduced
rate of release of virus particles; Pr78WT can first be
detected in the medium after 1 h (Fig. 3B), while Pr78∆KR
was first detected in the medium after 2 h (Fig. 3B). Thus,
Pr78∆KR efficiently assembled into procapsids and
released processed Gag (p27) in the culture medium with
kinetics similar to Pr78WT.
∆KKPKR intracellular procapsids are indistinguishable 
from WT procapsids
The metabolic labeling and cell fractionation experiments
provided biochemical evidence that the deletion of the
KKPKR motif did not affect the ability of Gag to assemble
into procapsids and be released from cells. Examining
cells expressing Pr78WT and Pr78∆KR by thin-section EM
provided further evidence of normal assembly. Both pro-
duce intracellular, spherical procapsids (70–90 nm dia.)
that have the characteristic, ring-shaped core typical of
immature particles (Fig. 3). In addition, wild-type procap-
sids were found near the nuclear membrane, which others
have shown to be the site of intracellular assembly [19]
and near intracellular membranes (Fig. 3A and 3C). Inter-
estingly, Sfakianos and Hunter have previously shown
that Pr78WT co-localizes with Rab11+ recycling endosomes
[33]. Whether the vesicles shown here are recycling endo-
somes is not yet known. Of note, we observed fewer
assembling, or fully assembled procapsids near the
nuclear membrane compared to wild-type (Fig. 3B and
3D) suggesting that at least part of the replication defect
Intracellular procapsid morphology viewed by electron microscopyFigur  3
Intracellular procapsid morphology viewed by electron microscopy. COS-1 cells were transfected with pSARM-4 (A and C) or 
the ∆KKPKR mutant (B and D) proviral DNAs. Wild-type and mutant procapsids observed in close proximity to the nuclear 
membrane (white arrow) and throughout the cytoplasm near intracellular vesicles (black arrows). Bars approximately 500 nm.
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may be due to defect in intracellular targeting of newly
synthesized Pr78∆KR proteins.
∆KKPKR Gag maturation and Envelope packaging
The cell fractionation and pulse-chase experiments com-
bined with the EM analyses showed that the ∆KKPKR
deletion mutant was released from cells as virus-like par-
ticles. Furthermore, the presence of reverse transcriptase
activity and the CA (p27) protein in the culture medium
of ∆KKPKR transfected cells suggest that the deletion did
not affect PR-mediated processing of Gag, Gag-Pro or
Gag-Pro-Pol (Fig. 1 and 2). The other Gag cleavage prod-
ucts (MA, p24/pp18, p12, NC, and p4) were not detected
in the [35S] methinione labeling experiments because they
do not contain a sufficient number of methionine resi-
dues for detection. Furthermore, these experiments could
not determine if the viral glycoproteins, SU and TM (gp70
and gp20, respectively) were incorporated into the
released particles because an anti-pr78-specific antibody
used for the immunoprecipitations. It was therefore pos-
sible that the KR box deletion mutation either inhibited
Env glycoprotein incorporation or precise Gag processing,
thus blocking infectivity. To address this possibility, we
looked for the presence of the Env glycoproteins and the
other Gag cleavage products in released virions. To this
end, COS-1 cells were transfected with pSARM4,
p∆KKPKR or an Env-deletion mutant, pMT.∆E and
labeled overnight with [3H] leucine. Viral particles were
pelleted through a 25% sucrose cushion, lysed, and
immunoprecipitated using an anti-M-PMV antisera that
recognizes the Gag cleavage products as well as gp70 and
gp20. Figure 4 shows both wild-type and ∆KKPKR mutant
particles contain the Env glycoproteins (gp70 and gp20)
and the mature Gag cleavage proteins (MA [p10], pp16,
p12, and CA [p27]). The NC (p14) and p4 cleavage prod-
ucts were not detected with the antiserum used. As
expected particles released from pMT.∆E transfected cells
did not contain the gp70 or gp20 glycoproteins. These
results demonstrate that the block to ∆KKPKR replication
is not due to abnormal Pr78∆KR processing or an inability
of the mutant particles to incorporate the viral glycopro-
teins.
Genome packaging
Having demonstrated that the deletion of the KR box did
not affect the packaging or processing of the gag-, pol-,
and env-encoded viral proteins, semi-quantitative RT-PCR
assays were utilized to address whether the deletion of the
KR box altered packaging of genomic RNA into virions.
Equivalent amounts of virus, normalized by p27 content
from wild-type and mutant virions were pelleted through
a 20% sucrose cushion and resuspended in PBS and the
viral RNAs were extracted. Two-fold serial dilutions of
viral RNAs were used for RT-PCR reactions using primers
to amplify CA-coding sequences. The relative amounts of
viral RNA that were packaged were estimated by determin-
ing the end-point dilution within which viral cDNAs
could be detected by ethidium bromide staining. As
shown in this representative experiment, the deletion of
the KKPKR motif resulted in a 6–8 fold decrease in
genome packaging, relative to wild-type (Fig. 5). Similar
results were found using northern blot and dot-blot anal-
yses of vRNAs using a riboprobe specific for M-PMV LTR
sequences (data not shown). We concluded from these
vRNA packaging assays that the deletion of the KR box sig-
nificantly reduced the efficiency of vRNA packaging.
Subcellular localization
Electron microscopic examination indicated that fewer
numbers of ∆KKPKR procapsids were present near the
nuclear membrane and suggested that the deletion of the
KR box influences intracellular targeting of Pr78∆KR to this
perinuclear site of assembly. This observation combined
with the finding that Pr78∆KR packages significantly less
vRNA into particles lead us to hypothesize that correct
Glycoprotein incorporation and Gag processingFigure 4
Glycoprotein incorporation and Gag processing. COS-1 cells 
were transfected with nothing (lane 1), pSAMR4 (lane 2), 
∆KKPKR (lane 3), or pMT ∆E (lane 4) and then labeled over-
night with [3H] leucine. Culture medium was filtered and viral 
particles were pelleted through a 20% sucrose cushion. The 
viral proteins present in the pellet were immunoprecipitated 
using goat anti-M-PMV antibodies. Positions of various viral 
proteins are indicated.
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intracellular targeting and vRNA packaging are linked.
This hypothesis is supported by previous studies with
Rous sarcoma virus (RSV) and bovine leukemia virus
(BLV) which demonstrated that basic residues in the
regions of Gag proteins distant from the RNA binding
motif within NC influences both Gag targeting and viral
RNA packaging [29,30,32,36].
Studies with RSV have shown that its Gag proteins cycles
through the nuclear compartment using a nonclassical
nuclear targeting sequence within the MA domain and is
exported out of the nucleus via the CRM-1 export path-
way. Scheifele et al. have shown that treating the RSV Gag-
expressing cells with the CRM-1 inhibitor leptomycin B
(LMB) results in a dramatic accumulation of RSV Gag pro-
teins within the nucleus. In addition, it has been shown
that RSV MA mutants that are not targeted to the nuclear
compartment are insensitive to LMB treatment and are
released from cells as virus-like particles, yet are not infec-
tious due to a defect in vRNA packaging. These results sug-
gests that nuclear localization of RSV Gag and genome
packaging are linked [29,36]. Likewise, Wang et al. have
shown that basic residues within the MA domain of BLV
are involved in vRNA packaging [30]. However, BLV Gag
was not detected in the nucleus of cells treated with LMV.
These results suggest that BLV Gag either does not enter
the nucleus or that Gag does enter the nucleus but is
exported by a CRM1-independent pathway.
To further explore the intracellular trafficking of Pr78WT
and Pr78∆KR, the steady-state intracellular locations of
both were analyzed by confocal microscopy. Figure 6,
which are representative z-sections of transfected COS-1
cells, shows that the highest concentration of both Pr78WT
and Pr78∆KR were routinely found throughout the cyto-
plasm. Interestingly, small amounts of Pr78WT were also
observed associated with the nuclear compartment. In
contrast, nuclear staining of Pr78∆KR was only occasionally
observed (Figure 6A and 6B, respectively). To examine if
M-PMV Gag transiently traffics through the nuclear com-
partment in a CRM-1-dependent manner similar to RSV,
we asked whether M-PMV Gag could be trapped within
the nucleus by inhibiting the CRM-1 nuclear export path-
way with LMB. As has been previously described [36], RSV
Gag-GFP proteins were readily concentrated within the
nucleus upon treatment with LMB (Fig. 6E–F). In contrast,
LMB did not concentrate either Pr78WT or Pr78∆KR in the
nucleus (Fig. 6A–D).
Although these immunofluorescence experiments dem-
onstrated that M-PMV does not utilize a CRM-1-depend-
ent nuclear export pathway, it is possible that M-PMV Gag
either enters the nucleus, and is exported in a CRM-1-
independent manner, or Gag does not enter the nucleus
but instead localizes to the nuclear pores. To distinguish
between these two possibilities, we utilized confocal
microscopy, an affinity-purified rabbit polyclonal anti-
Pr78 antibody and a monoclonal antibody (MAb414)
that recognizes conserved FG repeats of nuclear pore pro-
teins [37] to examine whether Gag co-localizes with
nuclear pores. Following confocal imaging of HeLa cells
expressing either Pr78WT or Pr78∆KR, 0.3 um optical z-sec-
tions were stacked and orthogonal views through the
nuclei were analyzed. In these cells, the nuclear pores were
easily identifiable as punctate staining areas on the
nuclear membrane. Moreover, Pr78WT was not randomly
dispersed within the nuclear compartment or around the
nuclear membrane but rather concentrated in distinct foci
in close proximity to nuclear pores (Fig. 6G–J). In contrast
Pr78∆KR did not readily associate with nuclear pores (Fig.
6K–N), but instead localized mainly in the cytoplasm and
as discrete foci adjacent to, but not associated with nuclear
pores. However, we occasionally, but very infrequently,
observed Pr78∆KR associating with nuclear pores.
Discussion
The results of the studies described here show that a
KKPKR sequence located near the carboxy-terminal end of
the M-PMV Np24 domain of Gag plays a critical role dur-
ing virus replication. Initial experiments showed that
deletion of this motif did not inhibit the release of virions
as demonstrated by the release of virion-associated RT
activity into the culture medium of transfected cells. How-
ever, this mutant was unable to replicate, similar to what
was observed when the entire Np24 domain was deleted
[35]. While it is possible that the replication defect was
due to the deletion inducing deleterious conformational
changes in Pr78, several observations argue that this is
unlikely. First, the mutant was capable of assembling into
spherical procapsids with morphologies indistinguisha-
ble from wild-type. Second, these mutant procapsids, like
wild-type, associated with intracellular membranes as has
been described as a normal transport pathway for several
retroviruses [33,38,39]. Finally, they packaged normal
levels of the viral glycoproteins, gp70 and gp20, into the
released virions. These results show that the deletion did
not significantly alter the confirmation of Pr78 and they
demonstrate that the basic residues in Np24 are not
involved in targeting Gag to cellular membranes or in
packaging the viral glycoproteins.
Further analyses showed that the deletion resulted in two
assembly-related defects, vRNA packaging and intracellu-
lar targeting. Semi-quantitative PCR, northern blot and
dot blot analyses routinely demonstrated that the mutant
packaged 6–8 fold less vRNA than did wild-type. In vitro
assembly assays have shown that assembly of RSV and
HIV-spherical capsids requires nucleic acids [26,40]. In
the absence of nucleic acids, Gag proteins assemble into
sheets and tubes. Although we have not yet determined
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whether the spherical, cytoplasmic procapsids assembled
from the ∆KKPKR mutant contained RNA (presumably
mainly cellular RNAs), we would assume that the RNA
content of those intracellular capsids is similar to that
found in the released capsids.
Several explanations could account for the failure of this
mutant to specifically package vRNAs. First, the Np24
domain may be directly involved in RNA packaging.
While there is no evidence that the Np24 domain directly
binds RNA or interacts with the NC protein in the virion,
the presence of these basic residues may help facilitate
NC-mediated vRNA packaging in a manner analogous to
that hypothesized for the MA domain of bovine leukemia
virus [30].
Another explanation for the defect in genome packaging,
although unlikely, is that the deletion disrupted the viral
RNA dimerization and/or packaging signals. While it has
been proposed that dimer formation is required for RNA
packaging, the relationship between dimer formation and
packaging is still unclear. Nonetheless, for RSV, MLV, and
HIV, the sequence elements involved in dimerization are
included in the packaging signals located near the 5'-end
of their respective gag genes. In addition, many in vivo
studies have shown that mutations that disrupt RNA
dimer formation also interfere with RNA packaging. For
M-PMV, the RNA dimer initiation sequence (DIS) has not
been precisely mapped. However, based on the mapping
of the DIS within RNA packaging signals in other retrovi-
ruses (reviewed in [41]), the M-PMV DIS is also likely to
be an integral part of the RNA packaging signal (Ψ).
Because the ∆KKPKR deletion is more than 400 nucle-
otides down-stream of Ψ packaging signal [42], it is
unlikely that the deletion mutation affected the cis-acting
elements required for vRNA dimerization or packaging.
We are currently determining if the few viral RNAs
detected in the ∆KKPKR particles exist as dimmers and
whether the mutant vRNA can be packaged in trans with
wild-type Gag.
Previous studies on M-PMV suggested that the Np24
domain is required for Pr78 stability. Yasuda and Hunter
[35] showed using pulse-chase experiments that deletion
of the entire Np24 domain resulted in a Gag protein that
when expressed in transfected cells, was more unstable
than wild-type. The data presented here suggests that
Np24, and perhaps more specifically the KKPKR motif,
also plays an important role in intracellular targeting of
Pr78. Based on the observations that relatively few
∆KKPKR mutant capsids were found in the perinuclear
region of the cytoplasm, which has been shown to be the
site of assembly, as well as the findings that wild-type Gag,
but not the mutant, localized with the nuclear pores, we
RT-PCR analysis of genome packaging in wild-type M-PMV and ∆KKPKR virionsFigure 5
RT-PCR analysis of genome packaging in wild-type M-PMV and ∆KKPKR virions. Purified RNA from equivalent amounts of 
virus was diluted 1:1,000 (lane 3) followed by 2-fold serial dilutions to 1:96,000 (lane 9). First-strand cDNA synthesis was car-
ried out using M-MLV RT and followed by PCR using oligos that amplify M-PMV CA sequences. Relative viral RNA packaging 
efficiencies were estimated by determining the end-point dilution in which viral PCR products could be detected by Ethidium 
bromide staining. U, untransfected (lane 1); C, RNA control – no reverse transcriptase added to RT-PCR reaction (lane 2).
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Subcellular localization of wild-type M-PMV Gag, ∆KKPKR Gag, and RSV Gag-GFP under steady state growth conditions or after treatment with LMBFigure 6
Subcellular localization of wild-type M-PMV Gag, ∆KKPKR Gag, and RSV Gag-GFP under steady state growth conditions or 
after treatment with LMB. HeLa cells were transfected with either pSARM-4, ∆KKPKR, or RSV Gag-GFP and left untreated or 
treated with LMB. The cells were fixed in methanol and the subcellular localizations of Gag were viewed by confocal micros-
copy using rabbit anti-Pr78 antibodies and Cy2 conjugated secondary antibodies. RSV Gag-GFP was directly visualized by fluo-
rescence of the Gag-GFP fusion protein. Drug treatments: Wild-type M-PMV (untreated, panel 6A), wild-type MPMV (LMB 
treated, panel 6B) ∆KKPKR (untreated, panel 6C, ∆KKPKR (LMB treated, panel 6D), RSV Gag-GFP (untreated, panel 6E), and 
RSV Gag-GFP (LMB treated, panel 6F). Colocalization of wild-type M-PMV Gag, ∆KKPKR, and nuclear pores. Transfected HeLa 
cells were fixed with 4% paraformaldyhyde, and permiablized with 0.2% TX-100. Wild-type Gag (panels G-J), ∆KKPKR Gag 
(panels k-N), and nuclear pore localization were visualized by confocal microscopy using affinity purified anti-Pr78 and MAb414 
antibodies, respectively, and counter stained with Cy2 anti-rabbit and Cy5 anti-mouse antibodies. 0.3 um Z-sections were 
stacked and orthogonal views through the cell were generated using Flowview imaging analysis software.
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hypothesize that the KKPKR motif plays a role in targeting
Gag to the site of genome packaging, which may be either
be at the nuclear pores, within the nucleus, as suggested
by Scheifele et al. [36], or in the cytoplasm juxtaposed to
the outer nuclear membrane.
Interestingly, the KKPKR motif resembles a classical
nuclear localization signal [43] and we have previously
found that over expression of the nuclear pore associated,
Ubc9 protein lead to a dramatic redistribution of Pr78 to
the nuclear compartment [44]. Experiments are in
progress to determine whether the KKPKR motif can func-
tion as a nuclear targeting signal when fused to a heterol-
ogous protein. If the KKPKR does function as an NLS to
cycle Pr78 through the nucleus during the virus life cycle,
as has been suggested for RSV, its export to the cytoplasm
does not utilize the CRM-1 pathway (Fig. 6B). An alterna-
tive hypothesis, which is consistent with the data pre-
sented here, is that the KKPKR sequence targets Pr78 to the
nuclear pore, where it first recognizes the vRNA during
Tap-mediated RNA export [45]. This Gag-vRNA complex
would then serve as the nucleation event for spherical cap-
sid assembly just outside of the nuclear pore where the
betaretroviruses are known to assemble.
A motif within the M-PMV MA domain called the cyto-
plasmic targeting/retention signal (CTRS), which is
located approximately 100 residues upstream of the
KKPKR motif, has also been implicated in directing Pr78
to the intracellular site of assembly. Mutant Pr78 proteins
(R55W) that contain an arginine to tryptophan substitu-
tion at position 55 in MA do not accumulate at the usual
cytoplasmic sites of assembly. Instead R55W-Pr78 pro-
teins are targeted the plasma membrane where they
assemble concomitantly with budding, as with the C-type
retroviruses [20]. This arginine is contained within an 18
amino acid sequence (residues 43–60) that is conserved
between M-PMV and MMTV. When these 18 residues were
inserted in the MA domain of C-type MLV Gag, MLV cap-
sid assembly occurred in the cytoplasm [46]. Whether or
not these altered MLV capsids assembled in the perinu-
clear/pericentriolar region of the cytoplasm was not
shown. It has, therefore, been suggested that these resi-
dues either target Pr78 molecules to the cytoplasmic
assembly site or they retain Pr78 at this site until the pro-
capsids are fully assembled.
We hypothesize that the KKPKR motif identified in this
study, which may be included in a larger motif that has yet
to fully defined, functions either prior to or separate from
the CTRS function. We speculate that the KKPKR motif is
involved in targeting Pr78 to the nuclear pore to facilitate
RNA packaging. Because only two copies of vRNA are
packaged into virions, only a few Gag proteins need to be
targeted there, which is consistent with the findings
present here that the majority of Gag proteins don't asso-
ciate with nuclear pores. Once Gag has associated with the
vRNA, the Gag-vRNA complex would then be transported
to the assembly site perhaps via the CTRS signal to initiate
spherical capsid assembly.
Materials and methods
DNAs
Plasmid pSARM4 is an infectious molecular clone of wild-
type M-PMV. Plasmid pMT.∆E is an env deletion mutant
of pSARM4 [47]. Deletion of the KKPKR motif was accom-
plished using the Altered Sites II Mutagenesis System
(Promega) as per manufacture's protocol. Briefly, the
1,307 bp, SphI-PvuII fragment (nt 171-1478) of pSARM4
was subcloned into the SmaI-SphI sites of pALTER. Muta-
genesis was carried out using the mutagenic oligonucle-
otide (5'-GTTTGTGCTCTTAACAGAACT
GGGAAAGTACTTGATAAACCTTTATCTTGTAGAGAGG),
to precisely delete amino acids 153 through 157 (KKPKR)
in M-PMV Gag. The mutation was subcloned back into
pSARM4 using SacI and PacI sites. After mutagenesis, plas-
mid DNAs were sequenced to ensure that unwanted
mutations were not inadvertently created. Plasmid
pETM100A is a prokaryote expression vector used to
express a (His)6-tagged M-PMV Gag protein in E. coli (32).
Plasmid pRS.V8-EGFP was used to express a RSV Gag-
EGFP fusion protein in mammalian cells (John Wills,
Pennsylvania State University College of Medicine) [29].
Cell lines and transfection
COS-1 and HOS cells were grown at 37°C with 5% CO2
in Dulbecco's modified Eagle's medium supplemented
with 10% fetal bovine serum. HeLa cells were grown in
RPMI 1640 medium supplemented with 10% fetal bovine
serum and 5% tryptose phosphate broth. DNA transfec-
tions were carried out using Fugene 6 (Roche Diagnostics,
Indianapolis, IN) following the manufacture's protocol.
Antibodies
Goat anti-M-PMV antibodies were obtained from Eric
Hunter (Emory University). Mouse monoclonal antibod-
ies that recognize the conserved FG repeats found in
nuclear pore complex proteins (MAb414) were purchased
from Covance Research Products (Berkely, CA). HRP-con-
jugated goat anti-rabbit IgG and HRP-conjugated goat
anti-mouse IgG were purchased from Amersham Pharma-
cia Biotech (Little Chalfont Buckinghamshire, England).
Cy2 conjugated donkey anti-rabbit and Cy5 conjugated
donkey anti-mouse were purchased from Jackson Immu-
noresearch Laboratories (West Grove, PA). Rabbit poly-
clonal anti-Pr78 (47) was affinity purified as follows. M-
PMV Gag proteins containing a carboxy-terminal (His)6
tag were expressed in E. coli BL21 (DE3) cells from the
expression plamsid pET.M100A for 4 hours in the pres-
ence of 0.1 mM IPTG. Cells were harvested by centrifuga-
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tion at 4,000 × g and lysed at room temperature in a
denaturing lysis buffer containing 8 M urea in TNI pH 8.0
buffer (50 mM Tris Cl pH 8.0, 150 mM NaCl and 0.5 mM
imidizole). Cellular debris was removed by centrifugation
at 10,000 × g and the supernatant was passed over an Ni-
NTA agarose nickel column (Qiagen Sciences, Maryland,
USA) and extensively washed in 8 M urea in TNI pH 6.5
buffer. The denatured Gag proteins on the column were
refolded using a slow (8 h), linear reduction of urea from
8 M to 0 M (in TNI buffer, pH 8.0) in a manner similar to
that described by Klikova et al. [48] who have shown that
M-PMV Gag proteins denatured in 8 M urea could be
refolded into a confirmations that are competent to
assemble into immature capsids in vitro by slowly remov-
ing the urea over an 8 hour period at 4°C. After refolding,
Gag proteins were eluted form the Ni2+ column using TNI
pH 8.0 buffer containing 0.1 mM EDTA. After exchanging
the TNI-EDTA buffer to pH7.2 Coupling Buffer (Pierce) by
dialysis, the Gag proteins were covalently coupled to acti-
vated agarose beads using the Amino-Link Plus kit (Pierce,
Rockford, Il) per manufacturer's protocol. Anti-Pr78 anti-
bodies in the immunized rabbit serum were affinity puri-
fied using the immobilized Gag column by standard
protocols [49].
Intracellular Gag Fractionation and Immunoblots
Intracellular Gag fractionation experiments were used to
assay intracellular procapsid assembly. 60 mm diameter
culture dishes containing either untransfected or trans-
fected COS-1 cells were lysed in 1 ml TX-100 lysis buffer
(0.25 M sucrose, 1.0 mM EDTA, 10 mM Tris-HCl [pH7.5],
0.14 M NaCl, 0.5% Triton X-100, 0.25% DOC) contain-
ing PMSF, leupeptin, pepstatin, and aprotinin for 30 min-
utes on ice. Cell debris and nuclei were removed by
centrifugation for 2 min in a microfuge. The pellets were
discarded and the capsid-containing supernatants were
fractionated by centrifugation through a 20% sucrose
cushion at 350,00 × g in a MLA-130 rotor for 30 minutes
at 4°C. The pelleted procapsids were lysed in 2× protein
loading buffer (10% glycerol, 2.3% SDS, 63 mM Tris-HCL
[pH6.8], 5% β-mercaptoethanol, and 0.01% bromophe-
nol blue). Lysates were boiled for 3 minutes, separated on
a 12% SDS PAGE gel, transferred to nitrocellulose. Viral
proteins were analyzed by western blot using polyclonal
anti-Pr78, HRP-conjugated goat anti-rabbit IgG, and
Western Lightning Chemiluminescence Reagent Plus
(Perkin-Elmer) as per manufacturers suggestions.
Radiolabeling and immunoprecipitation
For this, subconfluent 60 mm diameter tissue culture
dishes containing either untransfected and transfected
COS-1 cells were washed twice in DMEM without methio-
nine or cysteine (DMEM Met- Cys-) and starved in 4 ml of
DMEM Met- Cys- for 15 min at 37°C in 5% CO2. The
medium was replaced with 800 µl of DMEM Met- Cys-
containing 250 µCi [35S] methionine-cysteine (>1000 Ci/
mmol; NEN, Boston, MA). The cells were incubated for 30
minutes at 37°C, 5% CO2. Cells were either immediately
lysed (pulse) or washed with complete medium and then
incubated for 1, 2, 3, 4, or 8 hours in complete medium
(chase) prior to lysis.
Virion and cell lysis were lysed as follows. Culture
medium from each plate was collected and clarified by
centrifugation in a microfuge for 2 min at 13,000 rpms.
Virions were lysed by adjusting the culture medium to 1×
lysis buffer B by adding 1/5 volume of 5× lysis buffer B
(0.5% sodium dodecyl sulfate [SDS], 5% Triton X-100,
5% deoxycholate [DOC], 0.75 M NaCl, 0.25 M Tris-HCl
[pH 6.8]). Cell monolayers were lysed in 1 ml lysis buffer
A (Triton X-100, 1% DOC, 0.15 M NaCl, 0.05 M Tris-HCl
[pH 6.8]) containing PMSF, leupeptin, pepstatin, and
aprotinin for 30 minutes on ice. Cell debris and nuclei
were removed by centrifugation for 2 min in a microfuge.
The pellets were discarded and the capsid-containing
supernatants were adjusted to 1× lysis buffer B by adding
0.1% SDS. All lysates were precleared by incubation with
inactivated, formalin-fixed Staphylococcus aureus cells.
Viral proteins were immunoprecipitated from all samples
using Rbt anti-Pr78 antibodies and Staphylococcus aureus
cells as previously described [50]. Immunoprecipitates
were resuspended in protein loading buffer (10% glyc-
erol, 2.3% SDS, 63 mM Tris-HCL [pH6.8], 5% β-mercap-
toethanol, and 0.01% bromophenol blue), boiled for 3
minutes, separated by SDS PAGE gel (12% acrylamide),
and visualized by fluorography or analyzed by phosphor-
imaging using The Discovery Series Quantity One (Bio-
Rad, Hercules, CA).
Steady state radiolabeling with [3H] leucine was done to
assess glycoprotein incorporation and Pr78 processing.
Transfected COS-1 cells were starved in leucine-free
DMEM for 90 minutes, and labeled overnight with [3H]
leucine (500 µCi/ml, 173.0 Ci/mmol, NEN, Boston, MA).
The culture medium was filtered with a 0.45 µm syringe
filter, and [3H] leucine-labeled viruses were pelleted
through a 25% sucrose cushion by centrifugation at
350,000 × g in a TLA 100.3 rotor for 30 minutes at 4°C.
After the viral pellet was solublized in 1× lysis buffer B, the
viral proteins were using goat anti-M-PMV antibodies and
analyzed as described above.
Virus replication assay
The infectivity of wild-type and mutant viruses were deter-
mined by measuring the increase of reverse transcriptase
(RT) activity in the culture supernatants of inoculated
HOS cell cultures at various times postinfection. Culture
medium was harvested from COS-1 cells that had been
transfected 48 h previously with either wild-type or
mutant DNA. Loose cells and cellular debris were pelleted
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by centrifugation for 2 min in a microfuge and the level of
RT activity in the clarified culture medium was measured.
Hos cells were infected with equivalent amount of RT-
containing in the presence of 4.0 µg/ml of polybrene. Cul-
ture fluids were harvested at various days postinfection
and assayed for RT activity. RT assays were carried out by
pelleting virus from medium by centrifugation at 350,000
× g in a TLA 100.3 rotor for 30 minutes at 4°C. The viral
pellet was lysed in 12 µl of Virion Lysis Buffer (50 mM
Tris-HCl [pH 7.8], 100 mM KCl, 0.05% TX-100, 2 mM
diothiothreitol [dTT]) on ice for 15 min. 7.5 µl of virion
lysates were added to 30 µl of RT Reaction Buffer (50 mM
Tris [pH 8.0], 100 mM KCl, 2 mM dTT, 7.5 mM MgCl2)
with 8 µCi [32P] α-TTP (>1000 mCi/mmol, NEN) and
1.25 µg poly (A) – oligo (dT)15 (Roche). The RT reaction
was incubated at 37°C for 2 hours. 10 µl of the RT reac-
tion was spotted onto a piece of Whatman DE81 paper
and allowed to dry. The filter paper was washed twice for
15 min in 2× SSC buffer (0.3 M NaCl, 0.03 M Na Citrate),
twice briefly in 95% EtOH, and once in distilled water.
The filters were dried and [32P] incorporation was meas-
ured by scintillation counting.
RNA extraction and RT-PCR
Medium from transfected COS-1 cells were clarified and
virus was pelleted through a 20% sucrose cushion at
207,570 × g in an SW41 rotor for 2 hours at 4°C and
resuspended in 30 µl of PBS. The amount of viral particles
was normalized by quantitation of p27 detected by
immunobloting. RNA was extracted from equivalent
amounts of virus using QIAamp Viral RNA Mini Kit (Qia-
gen Sciences, Maryland, USA) as per manufacturers sug-
gestions. Purified RNA was treated with 1 U of Rnase-free
Dnase I (New England Biolabs, Inc., Berverly, MA) for 30
min at 37°C, followed by inactivation at 70°C for 30 min.
Purified RNA from equivalent amounts of virus was
diluted 1:1,000 followed by 2-fold serial dilutions. 5 µl of
diluted RNA was used for first-strand cDNA synthesis as
per manufacturers suggestions for M-MLV RT (Invitrogen)
using 500 ng of oligo (dT)12–18 (Ambion, Austin, TX).
First-strand cDNA (5 µl) were amplified by PCR using the
following oligos 5'-CCGCTCGAGCGGGCCGCCAT-
GCCGGTGGCTGAAACCGTTG and 5'-GCTCTAGAGCG-
GCGGCCATGGCCAGG to amplify M-PMV CA
sequences. The relative amount of viral RNA packaged
into viral particles was estimated by end-point dilution.
Electron microscopy
Transmission Electron Microscopy (TEM) was utilized to
view assembled intracellular procapsids. Transfected
COS-1 cells were fixed for 1 hour with two changes of 3%
glutaraldehyde in 0.1 M phosphate buffer (5 mM
NaH2PO4 and 5 mM phosphoric acid). The cells were
rinsed for 30 min with 0.1 M phosphate buffer, followed
by osmication (2% OsO4 in phosphate buffer) for 1 hour.
The cultures were washed and dehydrated with a graded
series of ethanol (25% 50%, 75%, 95% 100), followed by
a graded series of ethanol/Epon 812 (Shell) mixtures (3:1,
1:1, 1:3). The cells were infiltrated with pure Epon 812
and polymerized at 60°C for 48 hours. Thin sections were
made with a LBK Ultrotome III, mounted on copper grids,
and stained with 2% uranyl acetate and lead citrate. Thin
sections were examined and photographed with a
HitachiH-7500 transmission electron microscope oper-
ated at 60 Kv.
Subcellular localization
The intracellular localizations of Pr78Gag and Pr78∆KR pro-
teins were determined by confocal microscopy. Trans-
fected HeLa cells were grown on sterile coverslips in 35
mm culture dishes. At 48 hours post transfection, cells
were washed with PBS (137 mM NaCl2, 2.7 mM KCl2, and
8 mM Na2HPO4, 2 mM KH2PO4), fixed in either 4% para-
formaldyhyde in PBS for 20 minutes at room-temperature
and then subsequently permiabilized with 0.2% TX-100
in PBS for 5 minutes at room-temperature, or fixed in
100% methanol at -20°C for 10 minutes. The coverslips
were washed with PBS, and blocked with Blocking Buffer
1 (PBS, 0.2% tween 20, 0.4% fish skin gelatin [Sigma]) for
5 minutes, and then blocked with Blocking Buffer 2 (PBS,
0.2% tween 20, 2.5% goat serum [Sigma]) for 5 min.
Affinity purified anti-Pr78 and MAb414 (in PBS, 0.2%
tween 20, 2.5% goat serum) were incubated on the cover-
slips for 45 min at 37°C. The primary antibodies were
removed and the coverslips were blocked as they had been
previously. Cy2 and Cy5 conjugated secondary antibodies
(in PBS, 0.2% tween 20, 2.5% goat serum) were incubated
on the cover-slips for 30 min at 37°C and washed in PBS
with 0.2% tween 20. The coverslips were mounted on
slides using GEL-mount and analyzed by confocal micro-
scopy (Olympus FV500 w/upright BX Olympus flores-
cence microscope). 0.3 µm Z-sections were stacked and
orthogonal views through the cell were generated using
Flowview imaging analysis software (Olympus).
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